search
Back to results

A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)

Primary Purpose

NHL, NHL, Relapsed, Adult

Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
CLN-978
Sponsored by
Cullinan Oncology, LLC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for NHL focused on measuring Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Eastern Cooperative Oncology Group (ECOG) PS ≤ 2 Documented diagnosis of one of the below CD19+ B-cell neoplasms according to WHO classification (Swerdlow et al., 2016) or WHO classification 2008: Diffuse large B-cell lymphoma - de novo or transformed High-grade B-cell lymphoma Primary mediastinal large B-cell lymphoma Follicular lymphoma Mantle cell lymphoma Marginal zone lymphoma (nodal, extranodal, or mucosa-associated) Relapsed, progressive, and/or refractory disease after at least 2 lines of therapy. For Part B expansion cohorts: Cohort B1: R/R DLBCL that has relapsed after at least 2 prior therapies including a CD20 monoclonal antibody and anthracycline. Cohort B2: R/R FL (grade 1-3a) that has relapsed after at least 2 prior therapies including CD20 monoclonal antibody and an alkylating agent. Cohort B3: Other R/R B-NHL. Measurable disease defined as ≥1 measurable nodal lesion (long axis >1.5 cm and short axis >1.0 cm) or ≥1 measurable extra-nodal lesion (long axis >1.0 cm) on computed tomography (CT) scan or magnetic resonance imaging (MRI) AND baseline fluorodeoxyglucose-positron emission tomography (FDG-PET) scan demonstrating positive lesion(s) compatible with CT- or MRI-defined anatomical tumor sites. Laboratory parameters including the following: Lymphocyte count < 5 x 10^9/L Platelet count ≥ 75 x 10^9/L Absolute neutrophil count ≥ 1.0 x 10^9/L; growth factor support allowed in cases of documented bone marrow involvement Hemoglobin ≥ 9 g/dL, with or without transfusion Creatinine clearance ≥ 45 mL/min Total bilirubin ≤ 1.5 × upper limit of normal (ULN), except patients with confirmed Gilbert's Syndrome Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 × ULN (unless attributed to hepatic involvement by lymphoma) Exclusion Criteria: Primary CNS lymphoma or known CNS involvement by lymphoma at study screening Known past or current malignancy other than the inclusion diagnosis Known clinically significant cardiac disease Significant central nervous system disease Prior organ allograft Confirmed history or current autoimmune disorder or other disease requiring ongoing immune suppression Active Hepatitis C Virus (HCV), Hepatitis B Virus (HBV), or known Human Immunodeficiency Virus (HIV) infection Live virus vaccines within 28 days of the first dose of CLN-978, during treatment, and until the end of last dose of CLN-978 Known active, clinically significant bacterial, viral, fungal, mycobacterial, parasitic, or other infection, including coronavirus disease of 2019 (COVID-19) infection, at the time of enrollment or within 7 days of the first dose of CLN-978. Prior treatment with any of the following: Allogeneic HSCT Autologous HSCT within 30 days prior to the first dose of CLN-978 Chimeric antigen receptor T cell therapy (CAR-T) within 30 days prior to the first dose of CLN-978 Any investigational CD19 x CD3 T cell engager (TCE) Unconjugated CD19 monoclonal antibody ≤ 4 weeks prior to the first dose CLN-978 Radio-conjugated or CD19 antibody-drug conjugate ≤ 12 weeks prior to the first dose CLN-978 Investigational or standard of care monoclonal antibodies, chemotherapy, or other investigational agent ≤ 4 weeks or 5 half-lives, whichever is shorter, prior to the first dose of CLN-978 Radiation therapy (XRT), with the exception of focal treatment for symptom control, ≤ 4 weeks of the first dose of CLN-978 Woman of child-bearing potential who is pregnant, breast-feeding, or plans to become pregnant Male patients who plan to father a child or donate sperm within 120 days of last study drug administration

Sites / Locations

  • University of Alabama at Birmingham
  • City of HopeRecruiting
  • Winship Cancer Institute at Emory University
  • Massachusetts General Hospital
  • Hackensack University Medical Center
  • University of Texas Southwestern Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Part A Dose Escalation

Part B Dose Expansion

Arm Description

Patients with R/R B-NHL treated with CLN-978 in dose escalation cohorts

Patients with R/R DLBCL, R/R FL and other R/R B-NHL treated with CLN-978 at a dose selected from the Part A Dose Escalation arm.

Outcomes

Primary Outcome Measures

Safety and tolerability of CLN-978 based on AEs, AESIs, and SAEs
Incidence and severity of adverse events (AEs)/adverse events of special interest (AESIs)/serious adverse events (SAEs); incidence of dose interruptions and delays
Define dose regimen for CLN-978
Dose-limiting Toxicities (DLTs)

Secondary Outcome Measures

Assess preliminary efficacy of CLN-978 by overall response in patients with selective histologies of R/R B-NHL
Overall response rate (ORR)
Assess preliminary efficacy of CLN-978 by complete response in patients with selective histologies of R/R B-NHL
Complete response (CR)
Assess preliminary efficacy of CLN-978 by duration of response in patients with selective histologies of R/R B-NHL
Duration of response (DOR)
Select PK parameters of CLN-978: AUC
Area under-the-concentration-time curve of CLN-978
Select PK parameters of CLN-978: Cmax
Maximum concentration of CLN-978
Select PK parameters of CLN-978: Half-life
Half-life of CLN-978
Immunogenicity of CLN-978 and potential impact on drug exposure
Incidence of anti-drug antibodies to CLN-978

Full Information

First Posted
May 5, 2023
Last Updated
August 22, 2023
Sponsor
Cullinan Oncology, LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT05879744
Brief Title
A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)
Official Title
A Phase 1, Open-label, Dose Escalation and Dose Expansion Study of CLN-978 in Patients With Relapsed/Refractory (R/R) B-cell Non-Hodgkin Lymphoma (B-NHL)
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 31, 2023 (Actual)
Primary Completion Date
November 2026 (Anticipated)
Study Completion Date
April 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Cullinan Oncology, LLC

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
CLN-978-001 is a Phase 1, open-label, dose escalation and dose expansion study of CLN-978 in patients with Relapse/Refractory (R/R) B-cell Non-Hodgkin Lymphoma (B-NHL).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
NHL, NHL, Relapsed, Adult
Keywords
Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Sequential Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
90 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Part A Dose Escalation
Arm Type
Experimental
Arm Description
Patients with R/R B-NHL treated with CLN-978 in dose escalation cohorts
Arm Title
Part B Dose Expansion
Arm Type
Experimental
Arm Description
Patients with R/R DLBCL, R/R FL and other R/R B-NHL treated with CLN-978 at a dose selected from the Part A Dose Escalation arm.
Intervention Type
Drug
Intervention Name(s)
CLN-978
Intervention Description
CD19xCD3 T cell engager
Primary Outcome Measure Information:
Title
Safety and tolerability of CLN-978 based on AEs, AESIs, and SAEs
Description
Incidence and severity of adverse events (AEs)/adverse events of special interest (AESIs)/serious adverse events (SAEs); incidence of dose interruptions and delays
Time Frame
24 months
Title
Define dose regimen for CLN-978
Description
Dose-limiting Toxicities (DLTs)
Time Frame
24 months
Secondary Outcome Measure Information:
Title
Assess preliminary efficacy of CLN-978 by overall response in patients with selective histologies of R/R B-NHL
Description
Overall response rate (ORR)
Time Frame
24 months
Title
Assess preliminary efficacy of CLN-978 by complete response in patients with selective histologies of R/R B-NHL
Description
Complete response (CR)
Time Frame
24 months
Title
Assess preliminary efficacy of CLN-978 by duration of response in patients with selective histologies of R/R B-NHL
Description
Duration of response (DOR)
Time Frame
24 months
Title
Select PK parameters of CLN-978: AUC
Description
Area under-the-concentration-time curve of CLN-978
Time Frame
24 months
Title
Select PK parameters of CLN-978: Cmax
Description
Maximum concentration of CLN-978
Time Frame
24 months
Title
Select PK parameters of CLN-978: Half-life
Description
Half-life of CLN-978
Time Frame
24 months
Title
Immunogenicity of CLN-978 and potential impact on drug exposure
Description
Incidence of anti-drug antibodies to CLN-978
Time Frame
24 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Eastern Cooperative Oncology Group (ECOG) PS ≤ 2 Documented diagnosis of one of the below CD19+ B-cell neoplasms according to WHO classification (Swerdlow et al., 2016) or WHO classification 2008: Diffuse large B-cell lymphoma - de novo or transformed High-grade B-cell lymphoma Primary mediastinal large B-cell lymphoma Follicular lymphoma Mantle cell lymphoma Marginal zone lymphoma (nodal, extranodal, or mucosa-associated) Relapsed, progressive, and/or refractory disease after at least 2 lines of therapy. For Part B expansion cohorts: Cohort B1: R/R DLBCL that has relapsed after at least 2 prior therapies including a CD20 monoclonal antibody and anthracycline. Cohort B2: R/R FL (grade 1-3a) that has relapsed after at least 2 prior therapies including CD20 monoclonal antibody and an alkylating agent. Cohort B3: Other R/R B-NHL. Measurable disease defined as ≥1 measurable nodal lesion (long axis >1.5 cm and short axis >1.0 cm) or ≥1 measurable extra-nodal lesion (long axis >1.0 cm) on computed tomography (CT) scan or magnetic resonance imaging (MRI) AND baseline fluorodeoxyglucose-positron emission tomography (FDG-PET) scan demonstrating positive lesion(s) compatible with CT- or MRI-defined anatomical tumor sites. Laboratory parameters including the following: Lymphocyte count < 5 x 10^9/L Platelet count ≥ 75 x 10^9/L Absolute neutrophil count ≥ 1.0 x 10^9/L; growth factor support allowed in cases of documented bone marrow involvement Hemoglobin ≥ 9 g/dL, with or without transfusion Creatinine clearance ≥ 45 mL/min Total bilirubin ≤ 1.5 × upper limit of normal (ULN), except patients with confirmed Gilbert's Syndrome Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 × ULN (unless attributed to hepatic involvement by lymphoma) Exclusion Criteria: Primary CNS lymphoma or known CNS involvement by lymphoma at study screening Known past or current malignancy other than the inclusion diagnosis Known clinically significant cardiac disease Significant central nervous system disease Prior organ allograft Confirmed history or current autoimmune disorder or other disease requiring ongoing immune suppression Active Hepatitis C Virus (HCV), Hepatitis B Virus (HBV), or known Human Immunodeficiency Virus (HIV) infection Live virus vaccines within 28 days of the first dose of CLN-978, during treatment, and until the end of last dose of CLN-978 Known active, clinically significant bacterial, viral, fungal, mycobacterial, parasitic, or other infection, including coronavirus disease of 2019 (COVID-19) infection, at the time of enrollment or within 7 days of the first dose of CLN-978. Prior treatment with any of the following: Allogeneic HSCT Autologous HSCT within 30 days prior to the first dose of CLN-978 Chimeric antigen receptor T cell therapy (CAR-T) within 30 days prior to the first dose of CLN-978 Any investigational CD19 x CD3 T cell engager (TCE) Unconjugated CD19 monoclonal antibody ≤ 4 weeks prior to the first dose CLN-978 Radio-conjugated or CD19 antibody-drug conjugate ≤ 12 weeks prior to the first dose CLN-978 Investigational or standard of care monoclonal antibodies, chemotherapy, or other investigational agent ≤ 4 weeks or 5 half-lives, whichever is shorter, prior to the first dose of CLN-978 Radiation therapy (XRT), with the exception of focal treatment for symptom control, ≤ 4 weeks of the first dose of CLN-978 Woman of child-bearing potential who is pregnant, breast-feeding, or plans to become pregnant Male patients who plan to father a child or donate sperm within 120 days of last study drug administration
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Timna Serino
Phone
6174104650
Email
clinops@cullinanoncology.com
Facility Information:
Facility Name
University of Alabama at Birmingham
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35294
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mayur Narkhede, MD
Facility Name
City of Hope
City
Duarte
State/Province
California
ZIP/Postal Code
91010
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Geoffrey Shouse, MD
Facility Name
Winship Cancer Institute at Emory University
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30322
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kristie Blum, MD
Facility Name
Massachusetts General Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Erika Haydu, MD
Facility Name
Hackensack University Medical Center
City
Hackensack
State/Province
New Jersey
ZIP/Postal Code
07601
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sharon Dailey
First Name & Middle Initial & Last Name & Degree
Andrew Ip, MD
Facility Name
University of Texas Southwestern Medical Center
City
Dallas
State/Province
Texas
ZIP/Postal Code
75390
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Farrukh Awan, MD

12. IPD Sharing Statement

Learn more about this trial

A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)

We'll reach out to this number within 24 hrs